Latham & Watkins Advises Underwriters in scPharmaceuticals’ Public Offering of Common Stock

A capital markets team advised the underwriters in the transaction.

May 28, 2020

scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, has closed its underwritten public offering of 5,780,347 shares of its common stock at a public offering price of $8.65 per share, before deducting underwriting discounts and commissions and other offering expenses, for gross proceeds of approximately $50.0 million. All shares of common stock sold in the offering are being offered by scPharmaceuticals. The Company has also granted the underwriters a 30-day option to purchase from the Company up to an additional 867,052 shares of common stock at the public offering price, less underwriting discounts and commissions.

Latham & Watkins LLP represented the underwriters in the transaction with a capital markets deal team led by partners Peter Handrinos and Wesley Holmes, with associates Danny Shulman, Kiara Vaughn and Martha Anderson.  Advice was also provided on FDA regulatory matters by partner Ben Haas, with associate Chad Jennings; on tax matters by partner Jocelyn Noll, with associate Joseph Curran; and on intellectual property matters by partner Alan Tamarelli.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.